Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XALute: xaluritamig versus cabazitaxel or second androgen receptor-directed therapy in previously treated metastatic castration-resistant prostate cancer
2024-513968-25-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Apr 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of xaluritamig in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Amgen. Primary endpoint: Overall survival. Planned start Apr 2025; status: authorised.
02
Drugs
xaluritamig
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2024-513968-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513968-25-00.